Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 6/20 | 0.53 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.42 |
| ▸ | CNR1 | P21554 | 1/20 | 0.42 |
| ▸ | GGPS1 | O95749 | 3/20 | 0.41 |
| ▸ | KDM4C | Q9H3R0 | 3/20 | 0.41 |
| ▸ | PHF8 | Q9UPP1 | 2/20 | 0.41 |
| ▸ | KDM5A | P29375 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | BCHE | P06276 | 1/20 | 0.39 |
| ▸ | ACHE | P22303 | 1/20 | 0.39 |
| ▸ | KDM4A | O75164 | 1/20 | 0.39 |
| ▸ | KDM2A | Q9Y2K7 | 1/20 | 0.39 |
| ▸ | DNM1 | Q05193 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22564647 | 0.86 | EPHX2 (0.53) | EPHX2CNR1KDM4CPHF8KDM5A | |
| SCHEMBL24458133 | 0.85 | CA1 (0.41) | EPHX2CNR1KDM4CPHF8KDM5A | |
| SCHEMBL8702680 | 0.85 | EPHX2 (0.62) | EPHX2SIGMAR1CNR1KDM4CPHF8 | |
| SCHEMBL4885883 | 0.85 | EPHX2 (0.62) | EPHX2SIGMAR1CNR1KDM4CPHF8 | |
| SCHEMBL13997447 | 0.84 | GGPS1 (0.42) | EPHX2GGPS1KDM4CPHF8ALDH1A1 | |
| SCHEMBL25615767 | 0.84 | GGPS1 (0.42) | EPHX2GGPS1KDM4CPHF8ALDH1A1 | |
| SCHEMBL9315939 | 0.83 | EPHX2 (0.60) | EPHX2SIGMAR1CNR1KDM4CPHF8 | |
| SCHEMBL2484953 | 0.83 | EPHX2 (0.70) | EPHX2CNR1KDM4CPHF8KDM5A | |
| SCHEMBL21596652 | 0.83 | EPHX2 (0.70) | EPHX2CNR1KDM4CPHF8KDM5A | |
| SCHEMBL5293678 | 0.83 | EPHX2 (0.70) | EPHX2CNR1KDM4CPHF8KDM5A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12036078-B2 | Oral products and methods for producing the same | PolySpectra, Inc. (US) | 2024-07-16 | — | — | US | disclosed |
| US-11725077-B2 | Olefin metathesis photopolymers | PolySpectra, Inc. (US) | 2023-08-15 | — | — | US | disclosed |
| US-20180067393-A1 | PHOTOACTIVE CATALYST COMPOSITIONS | PolySpectra, Inc. | 2018-03-08 | — | — | US | disclosed |
| US-20150118188-A1 | DIRECT PHOTOPATTERNING OF ROBUST AND DIVERSE MATERIALS | CALIFORNIA INSTITUTE OF TECHNOLOGY | 2015-04-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180067393-A1 | PHOTOACTIVE CATALYST COMPOSITIONS | DRD4, DDT, LCP1 | EPHX2 3296/4885SIGMAR1 1890/4885CNR1 2560/4885 |
| US-12036078-B2 | Oral products and methods for producing the same | CROCC, RPAP1, RUVBL1 | EPHX2 603/4885SIGMAR1 4324/4885CNR1 4474/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.